STOCK TITAN

Precision BioSciences (NASDAQ: DTIL) amends loan and extends term to 2029

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Precision BioSciences, Inc. entered into a First Amendment to its Amended and Restated Loan and Security Agreement with Banc of California on June 10, 2026. This amendment extends the maturity date of the company’s Term Loan from June 30, 2027 to December 31, 2029, giving the company a longer period before the loan must be repaid under the existing facility.

Positive

  • None.

Negative

  • None.
Item 1.01 Entry into a Material Definitive Agreement Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement Financial
The company incurred a new significant debt or off-balance-sheet obligation.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Original Term Loan maturity June 30, 2027 Initial maturity date under Loan and Security Agreement
New Term Loan maturity December 31, 2029 Extended maturity under First Amendment
Original agreement date July 31, 2024 Date of Amended and Restated Loan and Security Agreement
Material Definitive Agreement regulatory
"Item 1.01 Entry into a Material Definitive Agreement."
A material definitive agreement is a legally binding contract that creates major, long‑term obligations or rights for a company, such as loans, asset sales, mergers, or supplier deals. Think of it like a mortgage or lease for a business: it can change future cash flow, risk and control, so investors watch these agreements closely because they can materially affect a company’s value, financial health and stock price.
Loan and Security Agreement financial
"First Amendment to Amended and Restated Loan and Security Agreement"
A loan and security agreement is a legal contract that sets out the amount, repayment schedule, interest and the rules a borrower must follow, and it names specific assets a lender can claim if the borrower fails to pay. Think of it like a mortgage or car loan where the lender holds a claim on collateral until the debt is repaid. Investors care because it determines a company’s repayment priorities, borrowing costs, operational limits and how easily creditors can seize assets in distress, all of which affect equity value and credit risk.
Term Loan financial
"extended the maturity date of the Term Loan from June 30, 2027, to December 31, 2029"
A term loan is a type of loan that is borrowed for a set period of time, with a fixed schedule for repaying the money, usually in regular payments. It matters to investors because it represents a company's borrowing costs and financial stability; reliable repayment of these loans can indicate strong financial health, while difficulties may signal potential risks.
Emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
0001357874FALSE00013578742026-06-102026-06-10

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
________________________________________________________
FORM 8-K
________________________________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 10, 2026
________________________________________________________
Precision BioSciences, Inc.
(Exact name of Registrant as Specified in Its Charter)
________________________________________________________
Delaware001-3884120-4206017
(State or Other Jurisdiction
of Incorporation)
(Commission File Number)(IRS Employer
Identification No.)
302 East Pettigrew St.
Suite A-100
Durham, North Carolina
27701
(Address of Principal Executive Offices)(Zip Code)
Registrant’s Telephone Number, Including Area Code: 919 314-5512
(Former Name or Former Address, if Changed Since Last Report)
________________________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading
Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.000005 per shareDTIL
The Nasdaq Capital Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.



Item 1.01 Entry into a Material Definitive Agreement.

On June 10, 2026, Precision BioSciences, Inc. (the “Company”) and Banc of California (the “Lender”) entered into a First Amendment to Amended and Restated Loan and Security Agreement (the “First Amendment”).. The First Amendment amended the Amended and Restated Loan and Security Agreement, dated July 31, 2024, between the Company and Lender (as amended, including the First Amendment, the “Loan and Security Agreement”). The First Amendment extended the maturity date of the Term Loan (as defined in the Loan and Security Agreement) from June 30, 2027, to December 31, 2029.
The foregoing description of the First Amendment does not purport to be complete and is qualified in its entirety by reference to the First Amendment, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.



Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement.

The information set forth in Item 1.01 of this current report on Form 8-K is incorporated by reference herein.



Item 9.01 Financial Statements and Exhibits.
(d)Exhibits
Exhibit
No.
Description
10.1
First Amendment to Amended and Restated Loan and Security Agreement.
104Cover Page Interactive Data File (embedded within the Inline XBRL document).



SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
PRECISION BIOSCIENCES, INC.
Date:June 16, 2026By:/s/ John Alexander Kelly
John Alexander Kelly
Chief Financial Officer

FAQ

What did Precision BioSciences (DTIL) change in its loan agreement?

Precision BioSciences amended its Loan and Security Agreement with Banc of California. The First Amendment extends the Term Loan maturity from June 30, 2027 to December 31, 2029, giving the company additional time before principal repayment is due.

Who is the lender in Precision BioSciences’ amended loan agreement?

The lender is Banc of California. Precision BioSciences and Banc of California entered into a First Amendment to the existing Amended and Restated Loan and Security Agreement, continuing their lending relationship while adjusting the Term Loan maturity date.

When does Precision BioSciences’ Term Loan now mature after the amendment?

After the amendment, Precision BioSciences’ Term Loan maturity date shifts to December 31, 2029. Previously, the maturity was June 30, 2027, so the change adds roughly two and a half years to the loan term.

When was the original Amended and Restated Loan and Security Agreement signed?

The original Amended and Restated Loan and Security Agreement between Precision BioSciences and Banc of California was dated July 31, 2024. The June 10, 2026 First Amendment modifies that agreement, primarily by extending the Term Loan maturity date.

What SEC item does this Precision BioSciences 8-K primarily relate to?

The 8-K primarily relates to Item 1.01, Entry into a Material Definitive Agreement. It also references Item 2.03 for creation of a direct financial obligation, incorporating the same loan amendment details by reference.

Filing Exhibits & Attachments

4 documents